The Unexpected Costs of Cancer Treatment: Out-of-Network Billing
When Barbara McAneny, MD, sees a patient, she focuses on the best approach for their health, including the ideal medication and referrals to the most qualified specialists. Dr McAneny, a medical...
View ArticleOral Oncology Parity Laws Don’t Make Medications More Affordable
Cancer care is haunted by issues surrounding cost and oral cancer drugs are a stark example. For patients with chronic myeloid leukemia (CML) and multiple myeloma (MM), orally administered drugs have...
View ArticleIntegrative Oncology: Using Evidence-Informed Medicine to Improve Patient...
Cancer is among the leading causes of death worldwide. New cancer cases per year may rise to 23.6 million by 2030.1 Yet, The American Institute for Cancer Research (AICR) estimates that at least half...
View ArticleThe Questionable Practice That Permeates Oncology Clinical Trials
There are questionable practices informing the design of modern oncology clinical trials. A clinical trial may be underpowered because it enrolls too few patients, thereby precluding investigators...
View ArticleA New Trend in Drug Development: Leveraging Data from Expanded Access
Overseen by the US Food and Drug Administration (FDA), expanded access has historically been a pathway that allows patients with serious conditions, such as cancer, who have no or limited treatment...
View ArticleImproving Cancer Pain Management Amid the Opioid Crisis
Physicians have long relied on opioids and similar pharmacologic therapies for pain, despite known risks of side effects or substance use disorders. There is a pressing need for safer and more...
View ArticleFirst Human Clinical Trial in US to Test the Use of CRISPR-Modified T Cells...
Three patients with advanced cancer have become the first in the US to be treated with their own CRISPR-Cas9 modified T cells. The work, recently published in Science,1 details the...
View ArticleFederal Ruling Puts Pressure on Clinical Trial Sponsors to Post Data
Data from potentially “hundreds” of clinical trials conducted between 2007 and 2017 for products approved by the US Food and Drug Administration (FDA) could be posted on ClinicalTrials.gov as a result...
View Article“Medical Distancing” May Help Protect Cancer Patients From Exposure to COVID-19
As the number of COVID-19 cases in the United States continues to grow, experts — including those in the cancer research community — are attempting to control the spread of the disease by promoting...
View ArticleNot Developing Any New Drugs Could Be EQRx’s Biggest Innovation
A company named EQRx made headlines in January 2020 when it raked in $200 million to embark on a promise to “remake medicine” — and to do it faster and at lower prices than the traditional...
View ArticleEarly Monitoring of Chronic Myeloid Leukemia Might Dictate TKI Switch
Patients with chronic myeloid leukemia in chronic phase (CML-CP) who do not respond to first-line imatinib may benefit from early monitoring in order to switch to treatment with dasatinib, according...
View ArticleResearchers Turn to Crowdsourcing to Learn More About COVID-19 and Cancer
As oncology researchers around the world race to solve the mysteries about how the novel coronavirus SARS-CoV-2 affects cancer patients, a challenge quickly became apparent: How can they get data fast...
View ArticleA New Look at the Dose-Response Relationship in Phase 1 Oncology Trials
The new generation of cancer drugs behave quite differently than cytotoxic therapies, and that may mean phase 1 trials need to be updated. That’s the message of a recent study reviewing the...
View ArticleGenomics Industry Tries New Strategies to Engage Community Oncologists
As the number of approvals for targeted cancer drugs continues to soar, genomics advocates have raced to get oncologists up to speed on how to routinely use these testing results when making treatment...
View ArticleClik here to view.
Has the Time for At-Home Cancer Care Finally Come?
As a radiation oncologist, Justin E. Bekelman, MD, periodically hears complaints from patients who ask why they can’t receive hormone injections and chemotherapy infusions at home. One woman called...
View ArticleStudy Provides Support for TKI Discontinuation in Some Patients With CML
The following article features coverage from the European Hematology Association 2020 virtual meeting. Click here to read more of Cancer Therapy Advisor‘s conference coverage. Results of a...
View ArticleWhy Cancer Centers May Need to Rethink the Hard Sell to Patients
Every oncologist has had to straddle the uncomfortable line between offering patients hope and keeping expectations in check. Yet what makes these conversations even more challenging is the pressure...
View ArticleConflicts of Interest Continue to Plague Oncology Guidelines and Research
Financial relationships between health care providers and the pharmaceutical/medical device industry have been shown to influence published treatment recommendations.1 Conflicts of interest are...
View ArticleResearchers Reveal Racial Disparities in Access to Remdesivir for Patients...
Results from an observational study revealed that patients with cancer who also were infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were treated with unproven,...
View ArticleHow Patients Lose Their Own Voices: Disparities in Patient-Reported Outcome...
Despite the importance of incorporating patient reported outcomes (PROs) into clinical trials, capture is inadequate. The most recent evidence of this comes from a recent study performed by Pugh et...
View Article